Rabbit Polyclonal GRPR Antibody

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human hepatocellular carcinoma tissue, A549 cells, Primary antibody: P03957(GRPR Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P03957(GRPR Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P03957(GRPR Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

GRPR (Gastrin-releasing peptide receptor), a G protein-coupled receptor, binds gastrin-releasing peptide (GRP) to regulate physiological processes like neurotransmission, cell proliferation, and hormone secretion. Overexpressed in cancers (e.g., prostate, breast, lung), GRPR is linked to tumor growth, angiogenesis, and metastasis, making it a therapeutic and diagnostic target.

GRPR antibodies are tools for detecting receptor expression in research and clinical settings. Monoclonal antibodies, designed for high specificity, are used in immunohistochemistry, flow cytometry, or Western blot to study GRPR distribution in tissues or tumor models. Some therapeutic antibodies aim to block GRP/GRPR signaling, inhibiting cancer progression, while others serve as carriers for drug conjugates or radiolabels in targeted therapy and imaging. Challenges include optimizing binding affinity, minimizing off-target effects, and addressing receptor internalization. Recent advances explore bispecific antibodies or combinations with checkpoint inhibitors to enhance efficacy.

Despite promise, clinical translation requires further validation of safety and biomarker-guided patient stratification. GRPR antibodies remain pivotal in unraveling GRPR biology and advancing precision oncology.